Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma

Sponsor
Samsung Medical Center
Study ID
NCT01965119
Phase
PHASE2
Status
Completed

Conditions

  • Primary Mediastinal Large B-cell Lymphoma
  • Relapsed or Refractory Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
19 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.

Study Details

The purpose of this study is that ruxolitinib may be a possible treatment option for relapsed or refractory patients with Hodgkin and primary mediastinal large B-cell lymphoma.

Key Dates

Start date
Nov 15, 2013
Status verified
Oct 2018
Primary completion
Jun 30, 2017
Completion
Sep 18, 2018

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib
    20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.

Primary Outcome Measure

To assess the efficacy of disease control including complete response (CR), partial response (PR) and stable disease (SD) [ Time Frame: From date of enrollment until the date first documented disease progression or unacceptable toxicity, whichever came first, assessed up to 48months ]

Related Studies